Authorized access interest continues to expand across regions Phase 3 BATTMAN trial commenced patient enrollment in April 2026, advancing BOT+BAL into pivotal evaluation Zydus collaboration closed in ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results